Decreased liver stiffness by transient elastography indicates lower incidence of hepatocellular carcinoma in patients with chronic hepatitis B

Yinghua Zhang, MD\textsuperscript{a}, Chuanfang Wang, MD\textsuperscript{b}, Hui Li, MD\textsuperscript{c}, Yuanyuan Ding, MD\textsuperscript{b,\textsuperscript{*}}

Abstract

The prognostic value of dynamic liver stiffness (LS) variation on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB) remains to be explored. We aim to compare HCC incidence in patients with compensated CHB-related cirrhosis with increased and decreased LS after nucleos(t)ide analog (NA) regimens.

A total of 168 patients with CHB-related compensated cirrhosis were divided into groups according to LS variation post NA treatment. The laboratory results of 2 groups were reviewed and investigated. The probability of HCC development among each group was analyzed and compared.

A total of 168 patients with CHB with compensated cirrhosis received NA treatment and Fibroscan. Child–Pugh score, alanine aminotransferase, total bilirubin level, status of hepatitis B e antigen, and serum hepatitis B virus DNA level were compared between groups. The cumulative probability of HCC development in patients with decreased LS was significantly lower than in patients with increased LS $(P < .05)$. Multi-variant analysis indicated that decreased LS was significantly associated with lower probability of HCC development (hazard ratio, 0.65; 95% confidence interval range, 0.33–0.84, $P < .05$).

Decreased LS after NA treatment indicates a lower HCC incidence in patients with CHB with compensated cirrhosis.

Abbreviations: ADV = adefovir, AFP = α-fetoprotein, ALB = albumin, ALP = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate aminotransferase, CHB = chronic hepatitis B, CT = computed tomography, CTP = Child–Trucott–Pugh score, ETV = entecavir, HBeAg = hepatitis B e antigen, HBV = hepatitis B virus, HCC = hepatocellular carcinoma, LAM = lamivudine, LoT = telbivudine, NAs = nucleos(t)ide analogs, TBIL = total bilirubin.

Keywords: chronic hepatitis B, cirrhosis, fibroscan, hepatocellular carcinoma, nucleos(t)ide analogs

1. Introduction

Hepatocellular carcinoma (HCC) accounts for ~7% of all cancer and is ranked as the 6th most common cancer worldwide.\textsuperscript{[1]} According to the 2015 China cancer survey, HCC is the 3rd most common cancer causing cancer-related deaths in China.\textsuperscript{[2]} Cirrhosis is one of the main risk factors of HCC in China and over 80% of patients with HCC have the background of cirrhosis.\textsuperscript{[3,4]} Hepatitis B virus infection in patients is the main cause of cirrhosis and chronic hepatitis B progress to cirrhosis at a rate of 2% per year.\textsuperscript{[5]}

Quantification of liver fibrosis and liver cirrhosis is essential for the establishment of prognosis and guidance of surveillance. Liver biopsy is the gold standard for the assessment of both liver fibrosis and cirrhosis. However, with the invasive feature and potential complications, liver biopsy is limited in serial assessment of chronic hepatic diseases.\textsuperscript{[6,7]} The histologic changes are not always distributed across the whole liver parenchyma, which increases sampling error.\textsuperscript{[8–11]}

Recent advances of noninvasive methods to assess chronic hepatic diseases have proved liver stiffness (LS) by transient elastography as a fast, simple, and safe procedure.\textsuperscript{[12,13]} It is efficient and safe to evaluate liver cirrhosis, assessing liver portal vein hypertension and predicting HCC development.\textsuperscript{[14–20]} LS can be measured by FibroScan (Echosens, Paris, France) through detecting the propagation speed of an elastic shear wave triggered by transducer, which is related to LS.\textsuperscript{[21]} High LS was reported to be associated with the risk of HCC development.\textsuperscript{[19]} But whether patients with CHB with different dynamic changes of LS after the initiation of anti-virus treatment will have different prognosis is not determined. Thus, we reviewed the changes of LS within 1 year after the anti-virus treatment in patients with CHB with cirrhosis and compared the HCC development in patients with increased and decreased LS variations.
2. Materials and methods

2.1. Patients and study design

All patients with CHB were diagnosed with compensated liver cirrhosis and received anti-hepatitis B virus (anti-HBV) treatment in Jining No 1 People’s Hospital and Heze Municipal Hospital (Shandong, China) from May 2012 to October 2014. Inclusion criteria were: diagnosed as HBV infection with compensated liver cirrhosis; Child–Pugh scoring ≤ 9; valid clinical characteristics and laboratory outcome in electronic medical record. The exclusion criteria were: HCC; HCV coinfection; alcoholic hepatic diseases; schistosomiasis; invalid clinical characteristics and laboratory outcomes; HCC during the 1st year after anti-virus treatment; serum viral load remains over 1000 copies/mL at the 6th month after anti-virus treatment. About 298 patients were recruited into this retrospective study and 94 patients were excluded due to HCV coinfection (n = 9), alcoholic hepatic diseases (n = 2), and invalid data (n = 72). About 28 patients were excluded during follow-up for HCC recurrence within 1 year. Serum viral load of 34 patients were over 1000 copies/mL at the 6th month and 30 patients were lost to follow-up. A total of 168 patients were included in this study.

This study was conducted under compliance with the Declaration of Helsinki and was approved by the Human Ethics Committee of Jining No 1 People’s Hospital and the Human Ethics Committee of Heze Municipal Hospital.

2.2. Diagnosis and anti-virus treatment

All patients were histologically confirmed with cirrhosis through liver biopsy or contrast-enhanced computed tomography (CT). HBV infection was diagnosed with positive serum viral marker and elevated serum HBV-DNA level (> 1000 copies/mL during 2 consecutive detection). Contrast-enhanced CT, ultrasonography, or liver biopsy was conducted to screen HCC recurrence within 1 year. Serum viral load of 34 patients were over 1000 copies/mL at the 6th month after anti-virus treatment. About 298 patients were recruited into this retrospective study and 94 patients were excluded due to HCV coinfection (n = 9), alcoholic hepatic diseases (n = 2), and invalid data (n = 27). About 28 patients were excluded during follow-up for HCC recurrence within 1 year. Serum viral load of 34 patients were over 1000 copies/mL at the 6th month and 30 patients were lost to follow-up. A total of 168 patients were included in this study.

All patients received nucleos(t)ide analogs (NAs) as anti-virus treatment.

2.3. Transient elastography

All scans were conducted in outpatient setting. The procedure was conducted as previously described.[23] All patients underwent at least twice LS measurements: 1 prior to anti-HBV treatment and the other after 1-year NA treatment. About 21 patients were excluded for insufficient measurement and regarded as invalid data.

2.4. Statistics

Continuous variables were expressed as mean ± standard deviation with normal distribution and median (range) without normal distribution. The comparison of continuous variables with or without normal distribution was analyzed with Student t test and Wilcoxon rank test, respectively. Chi-squared and Fisher test were applied for analysis of categorical variables. P < .05 was regarded as statistically significant. The univariate analysis was conducted through Kaplan–Meier statistics and Log-rank test. Multivariate analysis was assessed with Cox regression test. Variables with P < .05 were employed into the Cox regression model. P < .05 was considered as statistically significant. Statistics analysis was conducted with SPSS (version 16.0; SPSS Inc, Chicago, IL) software package. Figures were made with GraphPad Prism 5 software.

| Table 1 | Baseline characteristics. |
|---------|--------------------------|
| Variable | Value                    |
| Patients, n | 168                     |
| Male sex, n (%) | 114 (67.68)           |
| Age, M (range) | 50 (22–74)             |
| CTP class A/B/C, n (%) | 147/1/0 (93.04/6.96)   |
| ALT, IU/L, M (range) | 31 (11–46)             |
| AST, IU/L, M (range) | 27 (17–58)             |
| ALP, IU/L, M (range) | 57 (45–203)            |
| ALB, g/L, M (range) | 4.1 (2.8–6.1)          |
| PLT, 10^9/L, M (range) | 193.67 (89–267)       |
| INR, M (range) | 1.17 (1.10–1.56)       |
| Liver stiffness, kPa, M (range) | 8.9 (6.9–12.5)       |

AFP = α-fetoprotein, ALB = albumin, ALP = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate aminotransferase, CTP = Child–Trucott–Pugh score, HBeAg = hepatitis B e antigen, HBeAg rate (< HBeAg positive, n (%) 96 (60.76) vs > HBeAg positive, n (%) 67 (40.16), all the other parameters were comparable, ≤ HBeAg positive, n (%) 96 (60.76) (Fig. 1).

3. Results

3.1. Baseline characteristics

The baseline characteristics of whole patients in our study are presented in Table 1. A total of 168 patients were included in our study. Male patients were predominant (n = 114, 67.86%). The median age was 50 years old ranging from 22 to 74. The majority of patients were Child–Pugh A (n = 147, 93.04%). The median serum HBV DNA level was 4.1 log copies/mL and 96 patients (60.76%) were serum HBV DNA positive. The median maximum diameter of tumor was 3.6 (1–8) centimeter and the median α-fetoprotein (AFP) was 3.88 ng/mL. Median total bilirubin was 6.87 mmol/L and average alanine aminotransferase (ALT) level was 31 IU/L. The median LS was 8.9 (6.9–12.5) kPa.

3.2. Variation of LS after NA treatment

All the patients received at least twice transient elastography: 1 before anti-virus treatment and the other at the 12th month after anti-virus therapy. Of 168 patients, 85 patients (50.60%) had elevated LS (median change = 4.1 ± 1.1 kPa) and 83 patients (49.6%) experienced decreased LS (median change = 3.7 ± 1.4 kPa) compared to their baseline value. In patients with increased LS, 64 patients (75.29%) received entecavir (ETV), 12 patients (14.12%) received lamivudine (LAM), and 9 patients (10.59%) received tenofovir (TDF). For patients with decreased LS, 54 patients (65.06%) received ETV, 21 patients (25.30%) received LAM, and 8 patients (9.64%) received TDF. The clinical parameters of each group were presented in Table 2. Except from blood platelet count (PLT) (< .05), serum AST, alkaline phosphatase (ALP), INR, and α-fetoprotein (AFP) were comparable, include all the other parameters were comparable, include AAFP, TBL, ALT, alkaline phosphatase (ALP), and LS.

To investigate the potential difference of prognosis in 2 groups, we compared the HCC incidence 1 year after NA treatment. We used Kaplan–Meier survival analysis to conduct the cumulative probability of HCC development in 2 groups, the results showed that patients with decreased LS had a lower HCC incidence compared to patients with elevated LS (P < .05) (Fig. 1).
### Table 2

Comparison of baseline variables in patients with LS increased and decreased.

| Variable                  | LS increased | LS decreased | P    |
|---------------------------|--------------|--------------|------|
| Patients, n (%)           | 85 (50.60)   | 83 (49.40)   |      |
| Male sex, n (%)           | 65 (76.47)   | 59 (60.94)   | .53  |
| Age, M (range)            | 48 (27-73)   | 50 (22-74)   | .11  |
| CTP class A/B/C, n (%)    | 71 (47-203)  | 58 (45-102)  | .09  |
| A                         | 73 (85.88)   | 67 (80.72)   |      |
| B                         | 12 (14.12)   | 16 (19.28)   | .41  |
| C                         | 0            | 0            |      |
| HBV DNA, log copies/mL    | 5.3 (3.0-7.7)| 4.9 (3.0-6.8)| .13  |
| HBeAg positive, n (%)     | 61 (62.24)   | 35 (42.17)   | .03  |
| AFP, ng/mL, M (range)     | 6.77 (2.56-18)| 5.21 (1.19-21)| .72  |
| TBL, mmol/L, M (range)    | 4.78 (2.60-24.70)| 7.41 (3.90-21.60)| .08  |
| ALT, IU/L, M (range)      | 21 (11-38)   | 27 (19-46)   | .11  |
| AST, IU/L, M (range)      | 28 (17-46)   | 18 (17-58)   | .41  |
| ALP, IU/L, M (range)      | 71 (47-203)  | 58 (45-102)  | .09  |
| ALB, g/L, M (range)       | 4.7 (2.8-5.7)| 3.9 (2.8-6.1)| .64  |
| PLT, 10^9/L, M (range)    | 189.77 (103-267)| 213.52 (89-241)| .04  |
| PT, s, M (range)          | 13.2 (11.0-14.7)| 12.6 (11.0-15.6)| .77  |
| INR, M (range)            | 1.01 (0.87-1.54)| 0.88 (0.78-1.21)| .49  |
| Liver stiffness, kPa, M (range) | 8.1 (6.9-12.4) | 9.2 (7.4-12.5) | .16 |

### Table 3

Univariate and multivariate analyses of HCC development.

#### Univariate analysis

| HR (95% CI) | P-value | HR (95% CI) | P-value |
|-------------|---------|-------------|---------|
| Gender: male/female | 0.87 (0.37–1.59) | NS | |
| Child–Pugh score: A/B | 0.79 (0.31–1.32) | NS | |
| HBV DNA < 4 log copies/mL | 0.68 (0.33–0.97) | .05 | |
| HBV DNA increased | 2.13 (1.06–4.69) | <.05 | 1.43 (1.11–1.78) | <.05 |
| Total bilirubin: <24/≥24 μmol/L | 1.15 (0.69–1.93) | NS | |
| LS decreased/LS increased | 0.78 (0.43–0.97) | <.05 | 0.65 (0.33–0.84) | <.05 |

#### Multivariate analysis

| HR (95% CI) | P-value | HR (95% CI) | P-value |
|-------------|---------|-------------|---------|
| Gender: male/female | 0.87 (0.37–1.59) | NS | |
| Child–Pugh score: A/B | 0.79 (0.31–1.32) | NS | |
| HBV DNA < 4 log copies/mL | 0.68 (0.33–0.97) | .05 | |
| HBV DNA increased | 2.13 (1.06–4.69) | <.05 | 1.43 (1.11–1.78) | <.05 |
| Total bilirubin: <24/≥24 μmol/L | 1.15 (0.69–1.93) | NS | |
| LS decreased/LS increased | 0.78 (0.43–0.97) | <.05 | 0.65 (0.33–0.84) | <.05 |

### 3.3. Risk factors of HCC development

During the follow-up period, 82 patients (48.81%) developed HCC. In patients with increased LS, 49 patients (57.65%) experienced HCC development and 35 patients (42.17%) HBeAg seroconversion. Thirty-three patients (39.76%) in decreased LS experienced HCC development and 35 patients (42.17%) HBeAg seroconversion. Thirty-three patients (39.76%) in decreased LS experienced HCC development and 35 patients (42.17%) HBeAg seroconversion.

### Figure 1

The cumulative probability of hepatocellular carcinoma (HCC) development. The comparison of cumulative HCC development probability between LS increased group (red) and LS decreased group (blue). X-axis represented time (weeks), and Y-axis represented probability of HCC development.

### 4. Discussion

Although NAs have been proved to be effective in anti-HBV treatment as well as delaying HCC development,[24–26] Approximately 10% patients with effective NAs therapy are still at risk of HCC.[27–29] High LS by transient elastography were proved to be associated with HCC development and recurrence, but whether the variation of LS post to anti-virus treatment is associated with HCC development in patients with cirrhosis remains to be explored. Since liver fibrosis and cirrhosis can be quantified by measurement of LS, we supposed that dynamic variation of LS might reflect the progression or alleviation of liver tissue. Our study determined that decreased LS after effective anti-virus therapy was significantly related to lower HCC incidence (P < .05). As LS by transient elastography is noninvasive and safe compared to liver biopsy, our study suggested it may be applicable to serially assess the histology in patients with anti-HBV therapy.

As a retrospective study, we also suffered from the common flaws. During our design, to make potential groups comparable, we defined both inclusion and exclusion criteria, which caused a relatively small sample. The heterogeneity of anti-virus regimens limited our further analysis of possible relationships between LS and HCC. Further studies of prospective design are required to evaluate these issues.

### 5. Conclusion

Our study determined the significant association between LS variation and HCC development in patients with CHB with compensated cirrhosis. It suggested that LS by transient elastography is an effective serial assessment for hepatic disease progression.

### Author contributions

Yinghua Zhang and Chuanfang Wang contribute to patients follow-up, data collection and manuscript preparation.
References

[1] European Association for the Study of the Liver; European Organisation for Research and Treatment of CancerEASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56:908–43.

[2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115–32.

[3] Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335–52.

[4] Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology (Baltimore, Md) 2009;50:661–2.

[5] Lee HW, Ahn S H. Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients. World J Gastroenterol 2016;22:8314–21.

[6] Janes CH, Linder KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med 1993;118:96–8.

[7] Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014;20:473–85.

[8] Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C: HEPATOPATHY (Baltimore, Md) 2003;38:1449–57.

[9] Merat S, Sotoudehmanesh R, Nouraie M, et al. Sampling error in histopathology findings of nonalcoholic fatty liver disease: a post mortem liver histology study. Arch Iran Med 2012;15:418–21.

[10] Razzou V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898–906.

[11] Skrivenova S, Trainer TD, Krawitt EL, et al. Variability of grade and stage in simultaneous paired liver biopsies in patients with hepatitis C. J Clin Pathol 2007;60:321–4.

[12] Chen X, Zou H, Xiong L, et al. Predictive power of splenic thickness for post-hepatectomy liver failure in HBV-associated hepatocellular carcinoma patients. World J Surg Oncol 2017;15:216.

[13] Sasso M, Tengher-Barna I, Ziof M, et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(R): validation in chronic hepatitis C. J Viral Hepat 2012;19:244–53.

[14] Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology (Baltimore, Md) 2008;47:380–8.

[15] Deorsola L, Aidala E, Cascarano MT, et al. Liver stiffness modifications shortly after total cavopulmonary connection. Interact Cardiovasc Thorac Surg 2016;23:513–8.

[16] Janssens F, Spahr L, Rubbia-Brandt L, et al. Hepatic amyloidosis increases liver stiffness measured by transient elastography. Acta Gastroenterol Belg 2010;73:52–4.

[17] Koch A, Horn A, Duckers H, et al. Increased liver stiffness denotes hepatic dysfunction and mortality risk in critically ill non-cirrhotic patients at a medical ICU. Critical Care (London, England) 2011;15:R26.

[18] Lemoine M, Shimakawa Y, Nije R, et al. Food intake increases liver stiffness measurements and hampers reliable values in patients with chronic hepatitis B and healthy controls: the PROLIFICA experience in The Gambia. Aliment Pharmacol Ther 2014;39:188–96.

[19] Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology (Baltimore, Md) 2009;49:1954–61.

[20] Miller G, Reimann FM, Friedrich S, et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology (Baltimore, Md) 2008;48:1718–23.

[21] Adler M, Laroza I, Trovato FM, et al. Evaluating the risk of hepatocellular carcinoma in patients with prominently elevated liver stiffness measurements by FibroScan: a multicentre study. HPB (Oxford) 2016;18:678–83.

[22] Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646–9.

[23] Wu D, Chen E, Liang T, et al. Predicting the risk of postoperative liver failure and overall survival using liver and spleen stiffness measurements in patients with hepatocellular carcinoma. Medicine 2017;96:e7864.

[24] Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology (Baltimore, Md) 2013;58:98–107.

[25] Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521–31.

[26] Wong GL, Wong VW. Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. World J Gastroenterol 2013;19:6515–22.

[27] Arends P, Sonneveld MJ, Zoutendijk R, et al. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut 2015;64:1289–95.

[28] Vlachogiannakos J, Papatheodoridis G. Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. World J Gastroenterol 2013;19:8822–30.